🎥@MarianaBrandao0 of @JulesBordet addresses challenges in timely care for stage III #lungcancer patients, stressing the need for improved access to diagnostics and functional assessments for better surgical outcomes:

➡️⬅️

@BTOGORG #BTOG24 #LCSM

Challenges in timely assessment and access to care for lung cancer

Mariana Brandao, MD, PhD, from the Institute Jules Bordet in Brussels, Belgium, discusses the challenges in timely a...

ow.ly

🎥@gwalls89 of @QUBelfast sheds light on the NI-HEART analysis tackling cardiac toxicity post-radiotherapy for #lungcancer:

➡️⬅️

#BTOG24 @BTOGORG #LCSM

Addressing challenges in collecting cardiac toxicity data: NI-HEART analysis

Gerard Walls, MB MRCP MSc FRCR, Queens University in Belfast, UK, discusses the NI-HEART analysis aimed at addressin...

ow.ly

🎥@AdamJanuszewski of @BartsHospital shares insights from a session at #BTOG24 on novel therapeutics for #lungcancer, including ADCs and BiTEs, highlighting promising trials and challenges ahead:

➡️⬅️

@BTOGORG #LCSM #ImmunoOnc

Exploring novel therapeutics in lung cancer: insights from BTOG 2024

Adam Januszewski, St Bartholomew's Hospital in London, provides an overview of a session he chaired at the BTOG 20...

ow.ly

May is #SkinCancerAwarenessMonth 📣

@ProfGLongMIA discusses SECOMBIT: treatment sequencing in #metastaticmelanoma & incidence of #brainmetastasis

“#Immunotherapy should be given first for BRAF mutant patients, they do better, they survive longer”💡

👉

SECOMBIT: treatment sequencing in metastatic melanoma and incidence of brain metastasis

Georgina V. Long, PhD, MBBS, FRACP, FAHMS, The University of Sydney, North Sydney, Australia, discusses the Phase II...

ow.ly